All three vaccine formulations, SLA–OVA (adm), SLA–OVA (enc) and MS–OVA (enc) in combination with the checkpoint inhibitors anti-PD-1 and anti-CTLA-4 induced OVA-CD8+ T cells detectable in the spleen and tumor. This evidence concerns the gene CD8A and neoplasm.